The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The role of stromal cells and the tumour microenvironment in general in modulating tumour sensitivity is increasingly becoming a key consideration for the development of active anticancer therapeutics. Here, we discuss how these tumour-stromal interactions affect tumour cell signalling, survival, proliferation and drug sensitivity. Particular emphasis is placed on the ability of stromal cells to confer - to tumour cells - resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context. The mechanistic understanding of these microenvironmental interactions can influence the evaluation and selection of candidate agents for various cancers, in both the primary site as well as the metastatic setting. Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy. These recent advances can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“Hence, tumor-stromal interactions, the composition of the TME and tumor immune status all contribute to determining tumor growth, metastasis, angiogenesis and therapy resistance (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021), thereby critically influencing the clinical outcome of cancer patients.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“In addition, many studies have highlighted the critical importance of the microenvironment for promoting or suppressing tumor growth, invasion, metastasis, and response to therapy (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“The non‐malignant cells and matrixcomponents which make up the TME have been shown to playa role in tumor cell survival, proliferation,andtreatment resistance (48).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cited by
Items 101–200 of 491
Paul, A., Edwards, J., Pepper, C. J., & Mackay, S. P. (2018) · Cells · doi:10.3390/cells7100176 · Cited by 90
“Furthermore, the bone marrow stromal cells (BMSC) found in the MM tumour microenvironment have also been found to express high levels of NF-κB activation that helps to support the proliferation, survival and drug resistance of malignant plasma cells within the bone marrow niche [132].”
BackgroundCancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers
Raza, F., Zafar, H., You, X., Asifullah, K., Wu, J., & Ge, L. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01842e · Cited by 85
Liu, G., Ouyang, X., Sun, Y., Xiao, Y., You, B., Gao, Y., Yeh, S., Li, Y., & Chang, C. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0575-3 · Cited by 88
“tion of tumor progression, metastasis, and drug resistance [20, 21].”
BackgroundTranslational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures
Sun, Y. (2015) · Medicinal Research Reviews · doi:10.1002/med.21338 · Cited by 83
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
Watson, D. E., Hunziker, R., & Wikswo, J. P. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217732765 · Cited by 78
“Experimental evidence for the role of the extracellular environment on the development and maintenance of cell phenotype dates back to Mina Bissell’s pioneering work on culturing breast cancer cells and acinar tissues (reviewed in Schmeichel and Bissell11 and McMillin et al.12).”
BackgroundAnti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
Lupo, G., Caporarello, N., Olivieri, M., Cristaldi, M., Motta, C., Bramanti, V., Avola, R., Salmeri, M., Nicoletti, F., & Anfuso, C. D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00519 · Cited by 90
“In addition to being constituted by transformed cells, tumors are characterized by the presence of infiltrating different stromal cells, which are often the cause of therapy resistance, including the resistance to anti-angiogenic therapies (McMillin et al., 2013).”
BackgroundFan, F., Bashari, M. H., Morelli, E., Tonon, G., Malvestiti, S., Vallet, S., Jarahian, M., Seckinger, A., Hose, D., Bakiri, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.358 · Cited by 85
Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence
Das, M., & Law, S. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.08.011 · Cited by 77
Xu, M., Li, Y., Li, W., Zhao, Q., Zhang, Q., Le, K., Huang, Z., & Yi, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00064 · Cited by 89
He, C., Li, L., Guan, X., Li, X., & Miao, X. (2016) · Chemotherapy · doi:10.1159/000446361 · Cited by 89
Cancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 86
“So, tumor cells, which evade target therapy, may proceed by co‐ opting autocrine and paracrine signals in stroma by CAF, which justifies the simultaneous cotargeting of tumor cells and CAF, probably because of coupling the stroma induced lethal pathways.(87) Contrary to the above, the targeting of hedgehog (Hh) signal…”
BackgroundGreene, J. M., Gevertz, J. L., & Sontag, E. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00087 · Cited by 91
“Other characteristics of the tumor microenvironment influencing drug resistance include regions of acidity, immune cell infiltration and activation, and the tumor stroma.(1,6-10) Experimental and clinical research continues to shed light on the multitude of factors that contribute to cancer drug resistance.”
BackgroundJakubíková, J., Cholujová, D., Hideshima, T., Gronesova, P., Šoltýsová, A., Harada, T., Joo, J., Kong, S., Szalat, R. E., Richardson, P. G. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12643 · Cited by 84
“Similarly, primary malignant PCs have a low proliferation index in vitro, whereas the tumor microenvironment promote MM survival and proliferation [3].”
BackgroundKim, J.-Y., Welsh, E. A., Fang, B., Bai, Y., Kinose, F., Eschrich, S. A., Koomen, J. M., & Haura, E. B. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0506 · Cited by 76
“The importance of tumor–stromal interaction in modulating drug sensitivity is increasingly being recognized (57).”
BackgroundRix, L. L. R., Sumi, N. J., Hu, Q., Desai, B., Bryant, A. T., Li, X., Welsh, E. A., Fang, B., Kinose, F., Kuenzi, B. M., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abj5879 · Cited by 81
Seo, B. R., DelNero, P., & Fischbach, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.011 · Cited by 74
“, due to chronic inflammation, metabolic changes, or hormonal imbalance, enables the initiation and progression of malignancy [6-9] as well as the emergence of resistance [10, 11].”
BackgroundTowards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine
Xie, L., Ge, X., Tan, H., Xie, L., Zhang, Y., Hart, T. D., Yang, X., & Bourne, P. E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003554 · Cited by 81
“For example, tumor–stromal interactions play key roles in anticancer drug sensitivity [22].”
BackgroundExosomal MicroRNAs as Mediators of Cellular Interactions Between Cancer Cells and Macrophages
Kwon, Y., Kim, M.-S., Kim, Y., Jung, H. S., & Jeoung, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01167 · Cited by 81
“Accumulating evidence suggests that the tumor microenvironment plays a pivotal role in the development of anti-cancer drug resistance (99).”
BackgroundGuo, H., Xu, X., Zhang, J., Du, Y., Yang, X., He, Z., Zhao, L., Liang, T., & Guo, L. (2024) · Pharmaceuticals · doi:10.3390/ph17081048 · Cited by 83
“Consequently, in situ models can more accurately replicate the organ microenvironment that determines tumor cell phenotypes, including interstitial microenvironment interactions’ role in tumor growth and metastasis compared to heterotopic tumor xenotransplantation models [52].”
BackgroundImlimthan, S., Moon, E. S., Rathke, H. G., Afshar‐Oromieh, A., Rösch, F., Rominger, A., & Gourni, E. (2021) · Pharmaceuticals · doi:10.3390/ph14101023 · Cited by 80
“Within the TME, the interaction between tumor stroma (non-neoplastic part of the TME) and cancer cells is known to be the key parameter to direct tumor development and metastasis [22].”
BackgroundHAGEMANN, J., JACOBI, C., HAHN, M., SCHMID, V., WELZ, C., SCHWENK-ZIEGER, S., STAUBER, R., BAUMEISTER, P., & BECKER, S. (2017) · Anticancer Research · doi:10.21873/anticanres.11555 · Cited by 70
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Johnsen, H. E., Bøgsted, M., Schmitz, A., Bødker, J. S., El‐Galaly, T. C., Johansen, P., Valent, P., Zojer, N., Valckenborgh, E. V., Vanderkerken, K., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.138826 · Cited by 75
“Novel technologies and potential strategies include single-cell analyses,(79,80,36,49,55) transgenic mouse models(54,81-82) in addition to the xenogene immuno compromised SCID-hu models,(53) syngeneic BALB/c plasmacytoma or the 5T serie,(83) and investigations of oncogene transformation in primary organoid miniature t…”
BackgroundModeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach
Benzekry, S., Tracz, A., Mastri, M., Corbelli, R., Barbolosi, D., & Ebos, J. M. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1389 · Cited by 71
Tumor Microenvironment on a Chip: The Progress and Future Perspective
Ahn, J., Sei, Y., Jeon, N., & Kim, Y. (2017) · Bioengineering · doi:10.3390/bioengineering4030064 · Cited by 69
PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma
Tan, X., Banerjee, P., Pham, E. A., Rutaganira, F. U. N., Basu, K., Bota-Rabassedas, N., Guo, H.-F., Grzeskowiak, C. L., Liu, X., Yu, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax3772 · Cited by 70
Three-dimensional bio-printing: A new frontier in oncology research
Charbe, N. B., McCarron, P. A., & Tambuwala, M. M. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i1.21 · Cited by 78
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review
Brown, K. M., Xue, A., Mittal, A., Samra, J. S., Smith, R. C., & Hugh, T. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11184 · Cited by 75
“There is now good evidence highlighting the importance of these factors for drug resistance [15-18], tumour invasion [19], metastasis [20, 21] and recurrence [22].”
BackgroundO'Connor, R. A., Ooi, M. G. M., Meiller, J., Jakubíková, J., Klippel, S., Delmore, J. E., Richardson, P. G. G., Anderson, K. C., CLYNES, M. M., Mitsiades, C. S., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2136-7 · Cited by 72
“Conventional chemotherapeutics such as dexamethasone and doxorubicin as well as newer pharmacological agents have been shown to be attenuated in the presence of BMSCs [24, 40, 45, 46].”
Self-citationZhu, Y., Wen, L., Shao, S., Tan, Y., Meng, T., Yang, X., Liu, Y., Liu, X., Yuan, H., & Hu, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.023 · Cited by 66
Modelling glioma invasion using 3D bioprinting and scaffold-free 3D culture
van Pel, D. M., Harada, K., Song, D., Naus, C. C. G., & Sin, W. C. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-0469-z · Cited by 71
Ma, J., Dai, L., Yu, J., Cao, H., Bao, Y., Hu, J., Zhou, L., Yang, J., Sofia, A., Chen, H., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122026 · Cited by 68
Choe, C., Shin, Y.-S., Choi, S.-J., Lee, J., Kim, S., Cho, Y. B., Kim, J., & Kim, C. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89659 · Cited by 62
“How does CAF induce resistance to EGFR TKIs independent of an acquired secondary EGFR mutation? Emerging evidence indicates that CAFs provide a refuge for cancer cells from therapeutic drugs through secreted CAF-derived proteins including Wnt16B and hepatocyte growth factor, thus allowing the cancer cells to evade apo…”
BackgroundLiotti, A., Civita, E. L., Cennamo, M., Crocetto, F., Ferro, M., Guadagno, E., Insabato, L., Imbimbo, C., Palmieri, A., Mirone, V. G., et al. (2021) · The Prostate · doi:10.1002/pros.24117 · Cited by 72
Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant
Liang, Y., Liu, Z.-Y., Wang, P., Li, Y., Wang, R., & Xie, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.034 · Cited by 65
Pericytes, integral components of adult hematopoietic stem cell niches
da Bandeira, D. S., Casamitjana, J., & Crisan, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.006 · Cited by 66
“This resistance or susceptibility implies that bidirectional communication between leukemic cells and their microenvironment exists (McMillin et al., 2013).”
BackgroundTumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 64
Collins, A., Miles, G. J., Wood, J. P., MacFarlane, M., Pritchard, C. A., & Moss, E. L. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.020 · Cited by 61
3D Cancer Models: Depicting Cellular Crosstalk within the Tumour Microenvironment
Franchi-Mendes, T., Eduardo, R., Domenici, G., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13184610 · Cited by 67
Sun, Z., Li, R., Sun, J., Peng, Y., Xiao, L., Zhang, X., Xu, Y., & Wang, M. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11614 · Cited by 59
3D cell coculture tumor model: A promising approach for future cancer drug discovery
Xin, X., Yang, H. K., Zhang, F., & Yang, S. (2018) · Process Biochemistry · doi:10.1016/j.procbio.2018.12.028 · Cited by 64
April-Monn, S., Wiedmer, T., Skowronska, M., Maire, R., Lena, M. S., Trippel, M., Domenico, A. D., Muffatti, F., Andreasi, V., Capurso, G., et al. (2020) · Neuroendocrinology · doi:10.1159/000507669 · Cited by 62
Berg, E. L., Hsu, Y.-C., & Lee, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.013 · Cited by 66
Cytokine-mediated therapeutic resistance in breast cancer
Tan, C., Hu, W., He, Y., Zhang, Y., Zhang, G., Xu, Y., & Tang, J. (2018) · Cytokine · doi:10.1016/j.cyto.2018.03.020 · Cited by 58
MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer
Chen, W., Zhong, S., Ji, M., Pan, M., Hu, Q., Lv, M., Zhou, L., Zhao, J., & Tang, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-1417-4 · Cited by 56
“On one hand, cancerous cells exhibit a powerful ability to manipulate tumor microenvironment for their own benefits; on the other hand, stromal cells display supportive and enabling roles to confer treatment inefficacy [53].”
BackgroundMicrobiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Polak, R., Bierings, M., van der Leije, C. S., Sanders, M. A., Roovers, O., Marchante, J. R. M., Boer, J. M., Cornelissen, J. J., Pieters, R., den Boer, M. L., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193631 · Cited by 57
“The leukemic microenvironment or niche has been shown to protect leukemic cells from elimination by immune responses and chemotherapeutic agents and facilitates the development of drug resistance to classic and targeted chemotherapy.(37) Here, we show that MSCs can abrogate the effects of autophagy inhibition in ETV6R…”
BackgroundIdentification of cancer stem cells and a strategy for their elimination
Долгова, Е. В., Potter, E. A., Efremov, Y. R., Nikolin, V. P., Popova, N. A., Викторовна, Т. Т., Kozel, A. V., Minkevich, A. M., Andrushkevich, O. M., Zavyalov, E. L., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29854 · Cited by 54
Martin, S. Z., Wagner, D., Hörner, N., Horst, D. A., Lang, H., Tagscherer, K. E., & Roth, W. (2019) · BMC Cancer · doi:10.1186/s12885-019-6270-4 · Cited by 60
Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy
Brys, A. K., Gowda, R., Loriaux, D. B., Robertson, G. P., & Mosca, P. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.01.004 · Cited by 60
Cui, J., Wang, H., Zhang, X., Sun, X., Zhang, J., & Ma, J. (2020) · Aging · doi:10.18632/aging.103036 · Cited by 57
RetractedSidhic, J., Kuttithodi, A. M., Prasad, A., Tom, A., Mohan, P., Sarbadhikary, P., Narayanankutty, A., George, S., Abrahamse, H., & George, B. P. A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106622 · Cited by 69
Targeting Cell Metabolism as Cancer Therapy
Ngoi, N. Y. L., Eu, J. Q., Hirpara, J. L., Wang, L., Lim, J. S. J., Lee, S. C., Lim, Y., Pervaiz, S., Goh, B. C., & Wong, A. L. A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7947 · Cited by 59
“This current generation of clinical trials is expected to reveal combination strategies of CCM inhibitors with inhibitors of co-operative signaling as well as immune pathways (97).”
Peng, H., Xue, R., Ju, Z., Qiu, J., Wang, J., Yan, W., Gan, X., Tian, Y., Shen, H., Wang, X., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1038 · Cited by 54
“Mechanisms involved in drug resistance to HCC are complicated, and specific tumor-stromal interactions can affect tumor cells and their sensitivity to anti-cancer drugs (11).”
BackgroundGuo, Y., Li, Y., Cai, B., He, Q., Chen, G., Wang, M., Wang, K., Wan, X., & Yan, Q. (2021) · Aging · doi:10.18632/aging.202288 · Cited by 55
“However, TME diversity influences treatment response of targeted agents resulting in inconsistent outcomes among patients [3].”
Ovarian and cervical cancer patient derived xenografts: The past, present, and future
Boone, J. D., Dobbin, Z. C., Straughn, J. M., & Buchsbaum, D. J. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.022 · Cited by 56
Ricciardelli, C., Lokman, N. A., Sabit, I., Gunasegaran, K., Bonner, W. M., Pyragius, C. E., Macpherson, A. M., & Oehler, M. K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.006 · Cited by 51
Aberrant DNA Methylation of ABC Transporters in Cancer
Zappe, K., & Cichna‐Markl, M. (2020) · Cells · doi:10.3390/cells9102281 · Cited by 63
“In particular, the interplay of tumor and tumor microenvironment is essential [5].”
BackgroundVoissiere, A., Jouberton, E., Maubert, E., Degoul, F., Peyrode, C., Chezal, J.-M., & Miot-Noirault, É. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181340 · Cited by 49
Huang, H. H., Ferguson, I., Thornton, A. M., Bastola, P., Lam, C., Lin, Y.-H. T., Choudhry, P., Mariano, M. C., Marcoulis, M., Teo, C. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15521-4 · Cited by 51
“These cells home to the murine bone marrow, partially recapitulating the tumor microenvironment in human disease (McMillin et al., 2013).”
PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression
Gagliano, T., Shah, K., Gargani, S., Lao, L., Alsaleem, M. A., Chen, J., Ntafis, V., Huang, P., Ditsiou, A., Vella, V., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci128313 · Cited by 50
“Therefore, we focused on fibroblasts, the main stromal component in the TME, whose multiplex role in BC initiation, progression and therapy-resistance has been well described (7, 13, 14).”
BackgroundReconstructing the tumor architecture into organoids
Luo, Z., Zhou, X., Mandal, K., He, N., Wennerberg, W., Qu, M., Jiang, X., Sun, W., & Khademhosseini, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113839 · Cited by 52
The pharmacological point of view of resistance to therapy in tumors
Damia, G. L. M., & Garattini, S. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.008 · Cited by 51
Absence of primary cilia in cell cycle‐arrested human breast cancer cells
Nobutani, K., Shimono, Y., Yoshida, M., Mizutani, K., Minami, A., Kono, S., Mukohara, T., Yamasaki, T., Itoh, T., Takao, S., et al. (2014) · Genes to Cells · doi:10.1111/gtc.12122 · Cited by 46
“…et al. 2011) and are suitable to evaluate tumor–stromal interactions in the orthotopic © 2013 The Authors Genes to Cells © 2013 by the Molecular Biology Society of Japan and Wiley Publishing Asia Pty Ltd Genes to Cells (2014) 19, 141–152 143 and metastatic lesions in vivo (McMillin et al. 2013).”
BackgroundNF-κB dysregulation in multiple myeloma
Matthews, G. M., Simoes, R. D. M., Dhimolea, E., Sheffer, M., Gandolfi, S., Dashevsky, O., Sorrell, J., & Mitsiades, C. S. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.005 · Cited by 52
Self-citationA 3D‐Bioprinted Multiple Myeloma Model
Wu, D., Wang, Z., Li, J., Song, Y. Y., Pérez, M. E. M., Wang, Z., Cao, X., Cao, C., Maharjan, S., Anderson, K. C., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100884 · Cited by 53
Wagner, F., Holzapfel, B. M., McGovern, J., Shafiee, A., Baldwin, J., Martine, L. C., Lahr, C. A., Wunner, F. M., Friis, T., Bas, O., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.030 · Cited by 47
“Human tumor xenografts that interact with a murineo ly tissue microenvironment behave considerably different than in a human microenviron me t [49-54].”
BackgroundTherapeutic targeting of platelet-derived growth factor receptors in solid tumors
Ehnman, M., & Östman, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.847086 · Cited by 46
“It is now appreciated that therapeutic efficacy is dependent on a continuous crosstalk between tumor cells and nonmalignant stromal cells in the tumor microenvironment [4,5].”
BackgroundZhang, Y., Tan, W., Sultonova, R. D., Nguyen, D.-H., Zheng, J. H., You, S.-H., Rhee, J. H., Kim, S.-Y., Khim, K., Hong, Y., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122135 · Cited by 47
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43
New tools for old drugs: Functional genetic screens to optimize current chemotherapy
Gerhards, N. M., & Rottenberg, S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.001 · Cited by 47
“For instance, stroma-induced drug resistance has been described in several preclinical models for chemotherapeutic drugs such as resistance to doxorubicin, vincristine or vemurafenib (McMillin et al., 2013).”
BackgroundTranslational models of tumor angiogenesis: A nexus of in silico and in vitro models
Soleimani, S., Shamsi, M., Ghazani, M. A., Modarres, H. P., Valente, K. P., Saghafian, M., Ashani, M. M., Akbari, M., & Sanati‐Nezhad, A. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.01.013 · Cited by 46
Zhu, Y., Meng, T., Tan, Y., Yang, X., Liu, Y., Liu, X., Yu, F., Wen, L., Dai, S., Yuan, H., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00842 · Cited by 42
Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer
Yeh, W., Tsai, C., & Chen, D. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0630-2 · Cited by 43
“The heterogeneity of tumor microenvironment is believed to influence tumor progression by either direct cell-cell interactions with cancer cells, or by local release of soluble factors [39, 40].”
Prasmickaite, L., Tenstad, E. M., Pettersen, S., Jabeen, S., Egeland, E. V., Nord, S., Pandya, A. D., Haugen, M. H., Kristensen, V. N., Børresen‐Dale, A., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12319 · Cited by 45
“TME can influence both cancer progression and therapeutic responses (McMillin et al., 2013; Quail and Joyce, 2013), and tumor-related inflammation is now recognized as a hallmark of cancer (Hanahan and Weinberg, 2011).”
BackgroundZhu, Y., Yu, F., Tan, Y., Hong, Y. K., Meng, T., Liu, Y., Dai, S., Qiu, G., Yuan, H., & Hu, F. (2019) · Theranostics · doi:10.7150/thno.36334 · Cited by 43
“Accordingly, CAFs are increasingly considered as the primary noncancerous target for antitumor therapy, rather than a bystander [12].”
Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
“The role of stromal cells in facilitating metastasis and drug-resistance is becoming increasingly recognized [1, 2].”
Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer
Pardella, E., Pranzini, E., Nesi, I., Parri, M., Spatafora, P., Torre, E., Muccilli, A., Castiglione, F., Fambrini, M., Sorbi, F., et al. (2022) · Cells · doi:10.3390/cells11244026 · Cited by 43
“Indeed, the tumor stroma plays a pivotal role in cancer progression by establishing reciprocal and dynamic crosstalk with cancer cells promoting the acquisition of cancer malignancy [13], including the development of therapeutic resistance [14,15].”
BackgroundContext-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors
Conway, J. R. W., Warren, S. C., & Timpson, P. (2017) · Methods · doi:10.1016/j.ymeth.2017.04.014 · Cited by 42
Lamprecht, S., Sigal-Batikoff, I., Shany, S., Abu-Freha, N., Ling, E., Delinasios, G. J., Moyal-Atias, K., Delinasios, J. G., & Fich, A. (2018) · Cancers · doi:10.3390/cancers10030061 · Cited by 41
Cho, J., Hong, W. G., Jung, Y., Lee, J., Lee, E., Hwang, S., Um, H., & Park, J. K. (2015) · Tumor Biology · doi:10.1007/s13277-015-4548-y · Cited by 44
Yang, J., Huang, S., Cheng, S., Jin, Y., Zhang, N., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.701429 · Cited by 42
Simoes, R. D. M., Shirasaki, R., Downey-Kopyscinski, S. L., Matthews, G. M., Barwick, B. G., Gupta, V. A., Dupéré-Richer, D., Yamano, S., Hu, Y., Sheffer, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00550-x · Cited by 45
Self-citationIL-17 mediates resistance to anti-VEGF therapy
Maniati, E., & Hagemann, T. (2013) · Nature Medicine · doi:10.1038/nm.3333 · Cited by 40
In Vivo and Ex Vivo Pediatric Brain Tumor Models: An Overview
Li, Z., & Langhans, S. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620831 · Cited by 43
Liu, J., Cho, Y. B., Hong, H. K., Wu, S., Ebert, P. J., Bray, S. M., Wong, S. S., Ting, J. C., Calley, J. N., Whittington, C. F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67842-5 · Cited by 42
Organoid models in gynaecological oncology research
Semertzidou, A., Brosens, J. J., McNeish, I. A., & Kyrgiou, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102103 · Cited by 44
Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma
Sönnichsen, R., Hennig, L., Blaschke, V., Winter, K., Körfer, J., Haehnel, S., Monecke, A., Wittekind, C., Jansen‐Winkeln, B., Thieme, R., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.11.002 · Cited by 41
Using 3D in vitro cell culture models in anti-cancer drug discovery
Langhans, S. A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1912731 · Cited by 37
Ablation in Pancreatic Cancer: Past, Present and Future
Narayanan, G., Daye, D., Wilson, N. M., Noman, R., Mahendra, A. M., & Doshi, M. (2021) · Cancers · doi:10.3390/cancers13112511 · Cited by 35
“The tumor microenvironment, particularly the interaction of the stromal elements with the cancer cells, has been postulated to confer resistance to treatment, early recurrence, and metastasis [18,19].”
BackgroundXiao, Z., Liu, Y., Li, Q., Liu, Q., Liu, Y., Luo, Y., & Wei, S. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04348-5 · Cited by 36
Targeting cancer drug resistance utilizing organoid technology
Chai, C., Ji, P., Xu, H., Tang, H., Wang, Z., Zhang, H., & Zhou, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114098 · Cited by 38
Mutant p53—a potential player in shaping the tumor–stroma crosstalk
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz071 · Cited by 35
A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth
Lal-Nag, M., McGee, L., Guha, R., Lengyel, E., Kenny, H. A., & Ferrer, M. (2017) · SLAS Discovery · doi:10.1177/2472555216687082 · Cited by 33
Chiovaro, F., Martina, E., Bottos, A., Scherberich, A., Hynes, N. E., & Chiquet‐Ehrismann, R. (2015) · International Journal of Cancer · doi:10.1002/ijc.29565 · Cited by 37
“Discussion It is well known that paracrine signals released by breast cancer cells orchestrate the fate of stromal cells residing in the tumor microenvironment and vice versa.(4,22,23) Stromal cells are targeted by tumor-released factors and in response undergo myofibroblast-like differentiation to a so-called cancer-…”
BackgroundSuda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
Završnik, J., Butinar, M., Prebanda, M. T., Krajnc, A., Vidmar, R., Fonovič, M., GRUBB, A. O., Türk, V., Turk, B., & Vasiljeva, O. S. (2017) · Oncotarget · doi:10.18632/oncotarget.17379 · Cited by 35
“Another factor that can critically affect the development and progression of cancer is the crosstalk between tumor cells and the tumor stroma [38, 39].”
Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor
Pang, N., Li, J., Sun, A., Yang, Z., Cheng, S., & Qi, X. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s171224 · Cited by 33
Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
Kirouac, D. C., & Onsum, M. D. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.38 · Cited by 35
“54,55 These processes are known to play important roles in tumor biology and pharmacology, such that multiscale models must eventually describe tumors as complex tissues involving intercellular signaling networks, 56 rather than independent collections of cells.”
BackgroundUdartseva, O. O., Zhidkova, O. V., Ездакова, М. И., Ogneva, I. V., Andreeva, E. R., Buravkova, L. B., & Gollnick, S. O. (2019) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2019.111596 · Cited by 34
Metadata
- Authors
- McMillin, D. W., Negri, J. M., & Mitsiades, C. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Mitsiades, Constantine S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 217-228
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1980669422
- Cited by
- 474
- References
- 150
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 27 · 2023: 34 · 2022: 29 · 2021: 43 · 2020: 41 · 2019: 33 · 2018: 49 · 2017: 56 · 2016: 41 · 2015: 40 · 2014: 27 · 2013: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R0-1 50947)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- tumor microenvironment, stromal cells, drug resistance, drug sensitivity, anticancer drug discovery, preclinical models, orthotopic xenograft, metastasis
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Humans, Neoplasms, Stromal Cells, Drug Resistance, Neoplasm, Drug Discovery, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.